---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-034580"
form_type: "8-K"
ticker: "ACET"
cik: "0001720580"
company_name: "Adicet Bio, Inc."
filed_at: "2025-03-06T23:59:59+00:00"
generated_at: "2026-05-25T06:48:30.320485+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Adicet Bio Q4 net loss $0.32/share, cash $176.3M; expects ADI-001 LN data in 1H25

## Summary
- Q4 2024 net loss $28.7M ($0.32/share) vs. $29.5M ($0.69/share) in Q4 2023; full year net loss $117.1M.
- Cash, cash equivalents and short-term investments $176.3M as of Dec 31, 2024; expected to fund ops into 2H26.
- Phase 1 trial of ADI-001 in autoimmune diseases: LN patient preliminary data expected 1H25; enrollment for SLE, SSc, IIM, SPS to start 2Q25.
- ADI-270 Phase 1 in ccRCC: preliminary data expected 1H25; first patient dosed Dec 2024.
- Received FDA Fast Track Designation for ADI-001 in refractory SLE with extrarenal involvement and SSc (Feb 2025).

## SEC filing metadata
- accession: 0000950170-25-034580
- form_type: 8-K
- ticker: ACET
- cik: 0001720580
- company_name: Adicet Bio, Inc.
- filed_at: 2025-03-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720580/000095017025034580/0000950170-25-034580-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720580/000095017025034580/acet-20250306.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-034580
- JSON: https://secwatch.observer/filing/0000950170-25-034580.json
- Plain text: https://secwatch.observer/filing/0000950170-25-034580.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.